News & Publications
Press Releases
-
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
May 3, 2022 by NanOlogy
-
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
November 9, 2021 by NanOlogy
-
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
June 9, 2021 by NanOlogy
NanOlogy in the News
-
OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
September 16, 2021 by NanOlogy
-
Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 16, 2021 by NanOlogy
-
JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
March 26, 2021 by NanOlogy
Presentations
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
- NanOlogy General Presentation (May 2021)
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery
Publications
- Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
